MTNB (Matinas BioPharma Holdings Inc.) Earnings growth in current year
The development of a unique LNC drug delivery platform has established a powerful scientific foundation, confirming an annual earnings per share growth vector with a metric value of 0.00. Patent protection for encapsulation methods has created a high barrier to entry within the niche. Consequently, the launch of precision synthesis lines has ensured the stable production of drugs for clinical trials for Matinas BioPharma (MTNB).
Financial and market metric breakdowns for Matinas BioPharma (MTNB)
- share price and expert price forecast:
- business market valuation indicators:
- book capitalization data:
- debt burden and liquidity indicators:
Debt to Equity Matinas BioPharma|MTNB - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Matinas BioPharma Holdings Inc.|MTNB - Company Debts|Debts to Net Assets Matinas BioPharma Holdings|MTNB - Company Long-Term Debt|Company Current Liabilities Matinas BioPharma|Quick Liquidity Indicator matinasbiopharma.com
- earnings and valuation multiples information:
MTNB - Net Profit|Projected Future Earnings Matinas BioPharma|MTNB - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Matinas BioPharma Holdings, Inc.|MTNB - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Matinas BioPharma Holdings|MTNB - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Matinas BioPharma|MTNB - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth matinasbiopharma.com|MTNB - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Matinas BioPharma
- revenue and sales proceeds data:
Basic company analysis:MTNB - matinasbiopharma.com
This metric measures the annual rate of change in earnings per share, reflecting the efficiency of business capitalization. By analyzing EPS dynamics compared to the previous year, an investor assesses the growth or contraction rate of the actual return on invested capital. For Matinas BioPharma (MTNB), this metric remains negative, as the absence of revenue and the costs associated with nanocrystal clinical trials increase losses.
Main competitors
ASND: Net earnings per one share growth for the current year|MDGL (Madrigal Corp) - Earnings growth in current year|Earnings growth in current year Corcept Therapeutics|Earnings growth in current year RYTM|Earnings per share growth in current year AKRO (Akero Therapeutics, Inc.)|Earnings per share growth in current year metsera.com MTSR|MoonLake Corp (MLTX) - Earnings per share growth rate in current year|CRNX - Earnings per share growth in current year|NAMS: Earnings per share growth in current year|SLNO: Earnings growth in current year|FOLD - Expected net earnings per share growth this year|Earnings per share growth in current year 89bio Pharma|Agios Corp (AGIO) - Expected net earnings per share growth this year|Earnings per share growth in current year structuretx.com (GPCR)|Net earnings per share growth this year mimedx.com MDXG|Earnings per share growth in current year Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Earnings per share growth in current year|MBX: Net earnings per share growth this year|Altimmune Corp - Net earnings per one share growth for the current year|Aardvark Therapeutics Inc (AARD) - Earnings per share growth in current year|Net earnings per share change in current year Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Earnings growth in current year|Net earnings per share growth this year Biomea Fusion (BMEA)|Earnings growth in current year QNCX|Net earnings per one share growth for the current year GUTS|Earnings growth in current year VTVT (vTv Therapeutics Inc.)|Earnings per share increase in current year ATPC|Pluristem Therapeutics - Earnings growth in current year|Expected net earnings per share growth this year synlogictx.com SYBX|LPCN: Earnings growth in current year|SPRB (Spruce Biosciences, Inc.) - Earnings per share growth in current year|GLTO (galecto.com) - Earnings growth in current year|Net earnings per share growth this year carmellrx.com (CTCX)|Earnings per share growth in current year Lumos Pharma (LUMO)|ONVO (Organovo Holdings) - Earnings per share increase in current year|radiuspharm.com - Net earnings per share growth this year
